Background and HypothesisSchizophrenia affects approximately 1% of the global population, with early diagnosis critical for optimal treatment outcomes. Resting-state quantitative electroencephalography (qEEG) represents a promising, non-invasive biomarker. We hypothesized that 18 years after the seminal Boutros review, advances in qEEG methodology would demonstrate characteristic neurophysiological signatures distinguishing schizophrenia from healthy controls and first-episode psychosis.Study De